Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NCCAM

This article was originally published in The Tan Sheet

Executive Summary

Results from glucosamine/chondroitin trial in treating osteoarthritis (co-sponsored by National Institute of Arthritis & Musculoskeletal & Skin Diseases) will be available in roughly two years, NCCAM Director Stephen Straus, MD, tells House Appropriations/labor-HHS subcommittee at hearing March 28. No adverse events have been reported to date, he says. In addition, studies on effects of soy for menopause and Chinese herbal combination PC-SPES for prostate cancer are progressing and center's new PubMed database for CAM information is being visited at a promising rate, Straus notes. Subcommittee hearing was first to address NCCAM funding under new Chair Ralph Regula (R-Ohio), who replaced six-year former Chair John Porter (R-Ill.) following his retirement
Advertisement

Related Content

NCCAM PC-SPES Studies In Limbo After BotanicLab Closes Doors
NCCAM PC-SPES Studies In Limbo After BotanicLab Closes Doors
NCCAM PC-SPES Studies In Limbo After BotanicLab Closes Doors
Most Glucosamine/Chondroitin Supplements Pass Content, Dosage Tests – CR
Most Glucosamine/Chondroitin Supplements Pass Content, Dosage Tests – CR
Most Glucosamine/Chondroitin Supplements Pass Content, Dosage Tests – CR
Glucosamine/chondroitin
Glucosamine/chondroitin
Glucosamine/chondroitin

Topics

Advertisement
UsernamePublicRestriction

Register

PS092377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel